drugset / Trial / NCT03541356
Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal
RandomizedSequentialQuadruple-blindTreatment
Summary
A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Dose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of Decarboxylase Inhibitor to L-dopa Responsive Parkinson's Disease Patients
Timeline
- Start
- 2018-05-08
- Primary completion
- 2019-06-11
- Completion
- 2019-06-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carbidopa | Unknown | 7 mg | — |
| Subject | Levodopa | Small molecule | 35 mg | Intranasal |
| Subject | Levodopa | Small molecule | 70 mg | Intranasal |
| Subject | Levodopa | Small molecule | 140 mg | Intranasal |